|Free Dividend Report|
|Stock Splits Calendar|
|PRPO Stock Split History|
|Preferred Stock Newsletter|
|PRPO Options Chain|
|Stock Message Boards|
Precipio (PRPO) has 1 split in our PRPO split history database. The split for PRPO took place on April 29, 2019. This was a 1 for 15 reverse split, meaning for each 15 shares of PRPO owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 66.6666666666667 share position following the split.
When a company such as Precipio conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the PRPO split history from start to finish, an original position size of 1000 shares would have turned into 66.6666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Precipio shares, starting with a $10,000 purchase of PRPO, presented on a split-history-adjusted basis factoring in the complete PRPO split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-63.27%|
|Precipio is a healthcare solutions company focused on cancer diagnostics. Co.'s IV-Cell is a proprietary cell culture media that addresses the problem of selective and serial culturing. IV-Cell is a media that enables simultaneous culturing of four hematopoietic cell lineages. IV-Cell allows the laboratory technician to select any of the four lineages during the culturing process for analysis. In addition, Co. initially developed HemeScreen technology to target Myeloproliferative Neoplasms but it has enhanced HemeScreen into a suite of genetic diagnostic panels. Co.'s ICE COLD PCR is a proprietary specimen enrichment technology that increases the sensitivity of molecular based tests. According to our PRPO split history records, Precipio has had 1 split.|
|PRPO Split History Table|
|04/29/2019||1 for 15|
|Healthcare Stock Splits|
|PRPO is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: PRPO shares outstanding history